Granulin, a novel STAT3-interacting protein, enhances STAT3 transcriptional function and correlates with poorer prognosis in breast cancer

Genes and Cancer

Volumn 6, Issue 3-4, 2015, Pages 153-168

  Yeh, Jennifer E ^a   Kreimer, Simion ^b   Walker, Sarah R ^a,c   Emori, Megan M ^a   Krystal, Hannah ^a   Richardson, Andrea ^c   Ivanov, Alexander R ^b   Frank, David A ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Breast cancer; Interacting protein; STAT3

Indexed keywords

GRANULIN; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CARCINOGENIC ACTIVITY; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; DNA TRANSCRIPTION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE;

EID: 84949560488     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Society AC. Cancer Facts and Figures 2013. Atlanta, GA: American Cancer Society. 2013.
2. Foulkes WD, Smith IE and Reis-Filho JS. Triple-negative breast cancer. The New England journal of medicine. 2010; 363(20):1938-1948.
3. Society AC. Cancer Facts and Figures for African Americans 2013-2014. Atlanta, GA: American Cancer Society. 2013.
4. Sansone P and Bromberg J. Targeting the interleukin-6/Jak/ stat pathway in human malignancies. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012; 30(9):1005-1014.
5. Timofeeva OA, Chasovskikh S, Lonskaya I, Tarasova NI, Khavrutskii L, Tarasov SG, Zhang X, Korostyshevskiy VR, Cheema A, Zhang L, Dakshanamurthy S, Brown ML and Dritschilo A. Mechanisms of unphosphorylated STAT3 transcription factor binding to DNA. The Journal of biological chemistry. 2012; 287(17):14192-14200.
6. Liu L, McBride KM and Reich NC. STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(23):8150-8155.
7. Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R, Wu Z, Gonen M, Mulvey LA, Bessarabova MO, Huh SJ, Silver SJ, et al. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J Clin Invest. 2011; 121(7):2723-2735.
8. Shulga N and Pastorino JG. GRIM-19-mediated translocation of STAT3 to mitochondria is necessary for TNF-induced necroptosis. J Cell Sci. 2012; 125(Pt 12):2995-3003.
9. Wegrzyn J, Potla R, Chwae YJ, Sepuri NB, Zhang Q, Koeck T, Derecka M, Szczepanek K, Szelag M, Gornicka A, Moh A, Moghaddas S, Chen Q, Bobbili S, Cichy J, Dulak J, et al. Function of mitochondrial Stat3 in cellular respiration. Science. 2009; 323(5915):793-797.
10. Zhang Q, Raje V, Yakovlev VA, Yacoub A, Szczepanek K, Meier J, Derecka M, Chen Q, Hu Y, Sisler J, Hamed H, Lesnefsky EJ, Valerie K, Dent P and Larner AC. Mitochondrial localized Stat3 promotes breast cancer growth via phosphorylation of serine 727. The Journal of biological chemistry. 2013; 288(43):31280-31288.
11. Wang R, Cherukuri P and Luo J. Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. The Journal of biological chemistry. 2005; 280(12):11528-11534.
12. Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, Oh YT, Kim H, Rheey J, Nakano I, Lee C, Joo KM, Rich JN, Nam DH and Lee J. Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stem-like Cells. Cancer cell. 2013; 23(6):839-852.
13. Walker SR, Chaudhury M, Nelson EA and Frank DA. Microtubule-targeted chemotherapeutic agents inhibit signal transducer and activator of transcription 3 (STAT3) signaling. Mol Pharmacol. 2010; 78(5):903-908.
14. Ng DC, Lin BH, Lim CP, Huang G, Zhang T, Poli V and Cao X. Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. The Journal of cell biology. 2006; 172(2):245-257.
15. Nero TL, Morton CJ, Holien JK, Wielens J and Parker MW. Oncogenic protein interfaces: small molecules, big challenges. Nature reviews Cancer. 2014.
16. Collum RG, Brutsaert S, Lee G and Schindler C. A Stat3- interacting protein (StIP1) regulates cytokine signal transduction. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97(18):10120-10125.
17. Kwon MC, Koo BK, Moon JS, Kim YY, Park KC, Kim NS, Kwon MY, Kong MP, Yoon KJ, Im SK, Ghim J, Han YM, Jang SK, Shong M and Kong YY. Crif1 is a novel transcriptional coactivator of STAT3. The EMBO journal. 2008; 27(4):642-653.
18. Hossain DM, Panda AK, Manna A, Mohanty S, Bhattacharjee P, Bhattacharyya S, Saha T, Chakraborty S, Kar RK, Das T, Chatterjee S and Sa G. FoxP3 acts as a cotranscription factor with STAT3 in tumor-induced regulatory T cells. Immunity. 2013; 39(6):1057-1069.
19. Ma J and Cao X. Regulation of Stat3 nuclear import by importin alpha5 and importin alpha7 via two different functional sequence elements. Cellular signalling. 2006; 18(8):1117-1126.
20. Nallar SC, Kalakonda S, Lindner DJ, Lorenz RR, Lamarre E, Weihua X and Kalvakolanu DV. Tumorderived mutations in the gene associated with retinoid interferon-induced mortality (GRIM-19) disrupt its antisignal transducer and activator of transcription 3 (STAT3) activity and promote oncogenesis. The Journal of biological chemistry. 2013; 288(11):7930-7941.
21. Alvarez JV, Febbo PG, Ramaswamy S, Loda M, Richardson A and Frank DA. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res. 2005; 65(12):5054-5062.
22. Alvarez JV, Mukherjee N, Chakravarti A, Robe P, Zhai G, Chakladar A, Loeffler J, Black P and Frank DA. A STAT3 Gene Expression Signature in Gliomas is Associated with a Poor Prognosis. Translational oncogenomics. 2007; 2:99-105.
23. Bowman T, Garcia R, Turkson J and Jove R. STATs in oncogenesis. Oncogene. 2000; 19(21):2474-2488.
24. Dhingra K, Sahin A, Emami K, Hortobagyi GN and Estrov Z. Expression of leukemia inhibitory factor and its receptor in breast cancer: a potential autocrine and paracrine growth regulatory mechanism. Breast cancer research and treatment. 1998; 48(2):165-174.
25. Estrov Z, Samal B, Lapushin R, Kellokumpu-Lehtinen P, Sahin AA, Kurzrock R, Talpaz M and Aggarwal BB. Leukemia inhibitory factor binds to human breast cancer cells and stimulates their proliferation. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research. 1995; 15(10):905-913.
26. Avalle L, Pensa S, Regis G, Novelli F and Poli V. STAT1 and STAT3 in tumorigenesis: A matter of balance. Jak-Stat. 2012; 1(2):65-72.
27. Nelson EA, Walker SR, Kepich A, Gashin LB, Hideshima T, Ikeda H, Chauhan D, Anderson KC and Frank DA. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood. 2008; 112(13):5095-5102.
28. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C and Darnell JE, Jr. Stat3 as an oncogene. Cell. 1999; 98(3):295-303.
29. Chandriani S, Frengen E, Cowling VH, Pendergrass SA, Perou CM, Whitfield ML and Cole MD. A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response. PloS one. 2009; 4(8):e6693.
30. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA, Jr., Marks JR, Dressman HK, West M and Nevins JR. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006; 439(7074):353-357.
31. Lu X, Lu X, Wang ZC, Iglehart JD, Zhang X and Richardson AL. Predicting features of breast cancer with gene expression patterns. Breast cancer research and treatment. 2008; 108(2):191-201.
32. Cenik B, Sephton CF, Kutluk Cenik B, Herz J and Yu G. Progranulin: a proteolytically processed protein at the crossroads of inflammation and neurodegeneration. The Journal of biological chemistry. 2012; 287(39):32298-32306.
33. Lu R and Serrero G. Mediation of estrogen mitogenic effect in human breast cancer MCF-7 cells by PC-cell-derived growth factor (PCDGF/granulin precursor). Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(1):142-147.
34. Wang W, Hayashi J, Kim WE and Serrero G. PC cellderived growth factor (granulin precursor) expression and action in human multiple myeloma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2003; 9(6):2221-2228.
35. Lu R and Serrero G. Inhibition of PC cell-derived growth factor (PCDGF, epithelin/granulin precursor) expression by antisense PCDGF cDNA transfection inhibits tumorigenicity of the human breast carcinoma cell line MDA-MB-468. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97(8):3993-3998.
36. Hoque M, Young TM, Lee CG, Serrero G, Mathews MB and Pe’ery T. The growth factor granulin interacts with cyclin T1 and modulates P-TEFb-dependent transcription. Molecular and cellular biology. 2003; 23(5):1688-1702.
37. Serrero G, Hawkins DM, Yue B, Ioffe O, Bejarano P, Phillips JT, Head JF, Elliott RL, Tkaczuk KR, Godwin AK, Weaver J and Kim WE. Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinoma. Breast cancer research: BCR. 2012; 14(1):R26.
38. Abrhale T, Brodie A, Sabnis G, Macedo L, Tian C, Yue B and Serrero G. GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells. BMC Cancer. 2011; 11:231.
39. Elkabets M, Gifford AM, Scheel C, Nilsson B, Reinhardt F, Bray MA, Carpenter AE, Jirstrom K, Magnusson K, Ebert BL, Ponten F, Weinberg RA and McAllister SS. Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest. 2011; 121(2):784-799.
40. Liu S, Walker SR, Nelson EA, Cerulli R, Xiang M, Toniolo PA, Qi J, Stone RM, Wadleigh M, Bradner JE and Frank DA. Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2. Molecular cancer therapeutics. 2014; 13(5):1194-1205.
41. Toniolo PA, Liu S, Yeh JE, Moraes-Vieira PM, Walker SR, Vafaizadeh V, Barbuto JA and Frank DA. Inhibiting STAT5 by the BET Bromodomain Inhibitor JQ1 Disrupts Human Dendritic Cell Maturation. Journal of immunology. 2015.
42. Chin YR, Yoshida T, Marusyk A, Beck AH, Polyak K and Toker A. Targeting Akt3 signaling in triple-negative breast cancer. Cancer Res. 2014; 74(3):964-973.
43. Freeman E and Ivanov AR. Proteomics under pressure: development of essential sample preparation techniques in proteomics using ultrahigh hydrostatic pressure. Journal of proteome research. 2011; 10(12):5536-5546.
44. Cox J and Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nature biotechnology. 2008; 26(12):1367-1372.
45. Dicker L, Lin X and Ivanov AR. Increased power for the analysis of label-free LC-MS/MS proteomics data by combining spectral counts and peptide peak attributes. Molecular & cellular proteomics: MCP. 2010; 9(12):2704-2718.
46. Frank DA, Mahajan S and Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest. 1997; 100(12):3140-3148.
47. Walker SR, Nelson EA and Frank DA. STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas. Oncogene. 2007; 26(2):224-233.
48. Nelson EA, Walker SR, Alvarez JV and Frank DA. Isolation of unique STAT5 targets by chromatin immunoprecipitation-based gene identification. The Journal of biological chemistry. 2004; 279(52):54724-54730.